Conjoint Therapy News Timeline

Cognitive Behavioral Conjoint Therapy for PTSD: Study Closeout in July

In May 2018, the sixth dyad completed their long-term follow-up interview in our study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for posttraumatic stress disorder (PTSD) at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D.. The study close-out will be conducted in July 2018. Learn more...

Cognitive Behavioral Conjoint Therapy for PTSD: Sixth Dyad Completes Long-Term Follow-Up Interview

On May 28, 2018, the sixth dyad completed their long-term follow-up interview in our ongoing study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for posttraumatic stress disorder (PTSD) at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. Long-term follow-up data will provide additional information to guide the design of future trials. Enrollment for this study is closed.

The study enrolled dyads comprised of one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. MDMA was administered to both participants to help facilitate communication and connection between participants and therapists. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. This is the first MAPS-sponsored MDMA study conducted with VA-affiliated researchers and the first to employ measures developed for the DSM-5. Learn more...

Cognitive Behavioral Conjoint Therapy for PTSD: Sixth Dyad Receives Final Experimental Treatment

On October 28, 2017, the sixth dyad received their final experimental treatment in our ongoing study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for posttraumatic stress disorder (PTSD) at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. The third dyad completed the six-month follow-up interview on October 25.

The study enrolls dyads comprised of one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. This is the first MAPS-sponsored MDMA study conducted with VA-affiliated researchers and the first to employ measures developed for the DSM-5. Learn more...

Cognitive Behavioral Conjoint Therapy for PTSD: Fourth Dyad Completes Long-Term Follow-Up Interview

On March 3, 2018, the fourth dyad completed their long-term follow-up interview in our ongoing study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for posttraumatic stress disorder (PTSD) at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. Long-term follow-up data will provide additional information to guide the design of future trials. Enrollment for this study is closed.

The study enrolled dyads comprised of one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. MDMA was administered to both participants to help facilitate communication and connection between participants and therapists. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. This is the first MAPS-sponsored MDMA study conducted with VA-affiliated researchers and the first to employ measures developed for the DSM-5. Learn more...

Cognitive Behavioral Conjoint Therapy for PTSD: Sixth Dyad Receives Experimental Treatment

On October 10, 2017, the sixth dyad (pair of participants) received their first experimental treatment in our ongoing study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for posttraumatic stress disorder (PTSD) at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. The fifth dyad received their their final experimental session on October 12, and the second dyad completed the six-month follow-up interview on September 17.

The study enrolls dyads comprised of one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. This is the first MAPS-sponsored MDMA study conducted with VA-affiliated researchers and the first to employ measures developed for the DSM-5. Learn more...

Cognitive Behavioral Conjoint Therapy for PTSD: Fifth Dyad Receives Experimental Treatment

On August 26, 2017, the fifth dyad received their first experimental treatment in our ongoing study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for posttraumatic stress disorder (PTSD) at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D.

The study enrolls dyads comprised of one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. This is the first MAPS-sponsored MDMA study conducted with VA-affiliated researchers and the first to employ measures developed for the DSM-5. Learn more...

Cognitive Behavioral Conjoint Therapy for PTSD: Fourth Dyad Finishes Treatment

On July 30, 2017, the fourth dyad finished experimental treatment in our study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. The fifth dyad participated in their first preparation session on August 14. Four dyads have finished receiving experimental treatments, and will now move on to follow-up interviews.

The study enrolls dyads comprised of one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. This is the first MAPS-sponsored MDMA study conducted with VA-affiliated researchers and the first to employ measures developed for the DSM-5. Learn more...

View the full newsletter

Cognitive Behavioral Conjoint Therapy for PTSD: Fourth Dyad Begins Treatment

On July 7, 2017, the fourth dyad received their first experimental treatment our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for posttraumatic stress disorder (PTSD) at our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. The fourth dyad was enrolled on June 29. Three dyads have finished receiving experimental treatments, and will now move on to follow-up interviews.

The study will enroll dyads comprised of one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. This is the first MAPS-sponsored MDMA study conducted with VA-affiliated researchers and the first to employ measures developed for the DSM-5. There are several important reasons to include significant others in PTSD treatment, in addition to the data supporting the efficacy of CBCT for PTSD. Learn more...

View the full newsletter

Conjoint Therapy for PTSD: First Pair of Participants Complete Six-Month Follow-Up Interview

On March 11, 2017, the first pair of participants completed their six-month follow-up interview in our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD in our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. The study will enroll 10 dyads, with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. Three dyads have completed treatment so far. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. Learn more...

Conjoint Therapy for PTSD: Third Pair of Participants Receive Treatment

On March 10, 2017, the third pair of participants received their second experimental treatment in our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD in Charleston, South Carolina. The study will enroll 10 dyads, with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. Learn more...

Conjoint Therapy for PTSD: Second Pair of Participants Receive Treatment

On January 30, 2017, the second pair of participants received their first experimental treatment in our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD in Charleston, South Carolina. This pair (dyad) was officially enrolled on January 28, 2017. The study will enroll 10 dyads, with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. Learn more...

Conjoint Therapy for PTSD: First Pair of Participants Receive Second Treatment

On August 23, 2016, the first pair of participants received their second experimental treatment in our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD in Charleston, South Carolina. Final outcome measures for this pair (dyad) will be collected during the one-month follow-up taking place on October 9, 2016. The study will enroll 10 dyads, with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. We are currently screening additional local participants for this study.

Conjoint Therapy for PTSD: First Pair of Participants Receive Treatment

On August 6, 2016, the first pair of participants received an experimental treatment session in our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for treating PTSD. This dyad was officially enrolled on August 5. Led by Principal Investigator Michael Mithoefer, M.D., and Sub-Investigator Candice Monson, Ph.D., this is a pilot Phase 1/Phase 2 open-label study exploring CBCT integrated with MDMA-assisted psychotherapy for the treatment of chronic posttraumatic stress disorder (PTSD). Dr. Monson is a leading expert on individual and conjoint cognitive therapies to treat PTSD.

The study will enroll 10 dyads, each pair with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. This is the first MAPS-sponsored MDMA study to employ measures developed for the DSM-5. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The study has received approval from all necessary government agencies, and will begin screening local participants residing around South Carolina for enrollment this summer. Learn more...

Conjoint Therapy: DEA Approves Study Protocol

On June 14, 2016, the U.S. Drug Enforcement Administration (DEA) approved the protocol for our upcoming study of MDMA-assisted psychotherapy for PTSD in couples. Led by Principal Investigator Michael Mithoefer, M.D., and Sub-Investigator Candice Monson, Ph.D., this will be a pilot Phase 1/Phase 2 open-label study exploring Cognitive-Behavioral Conjoint Therapy (CBCT) integrated with MDMA-assisted psychotherapy for the treatment of chronic posttraumatic stress disorder (PTSD). Dr. Monson is a leading expert on individual and conjoint cognitive therapies to treat PTSD.

The study will enroll 10 dyads, each pair with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. This is the first MAPS-sponsored MDMA study to employ measures developed for the DSM-5. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. The study has received approval from all necessary government agencies, and will begin screening local participants residing around South Carolina for enrollment this summer. Learn more about participating in this study...

Conjoint Therapy: IRB Approves Study Protocol

On March 16, 2016, the Independent Review Board (IRB) approved the protocol for our upcoming study of MDMA-assisted psychotherapy for PTSD in couples. Taking place in Charleston, South Carolina, and led by Principal Investigator Michael Mithoefer, M.D., and Sub-Investigator Candice Monson, Ph.D., this will be a pilot Phase 1/Phase 2 open-label study exploring Cognitive-Behavioral Conjoint Therapy (CBCT) integrated with MDMA-assisted psychotherapy for the treatment of chronic posttraumatic stress disorder (PTSD). The study will enroll 10 participant pairs, each with one participant diagnosed with PTSD, and one concerned significant other without PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. We anticipate starting the study in June 2016, once it has been approved by the Drug Enforcement Administration (DEA).

Conjoint Therapy: FDA Accepts New Study Protocol

On January 26, 2016, the U.S. Food and Drug Administration (FDA) accepted the protocol for our upcoming study of MDMA-assisted psychotherapy for PTSD in couples. Led by Principal Investigator Michael Mithoefer, M.D., and Sub-Investigator Candice Monson, Ph.D., this will be a pilot Phase 1/Phase 2 open-label study exploring Cognitive-Behavioral Conjoint Therapy (CBCT) integrated with MDMA-assisted psychotherapy for the treatment of chronic posttraumatic stress disorder (PTSD). Candice Monson, a developer of CBCT, was introduced to MAPS by the U.S Department of Veterans Affairs National Center for PTSD.

The study will enroll 10 pairs of participants, each with one participant diagnosed with PTSD, and one concerned significant other who does not have PTSD. There are several important reasons to include significant others in PTSD treatment, in addition to the data supporting the efficacy of CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists.